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Background. Knowledge regarding prevalence of HEV in general population can be an indicator of the public health and hygiene.
Therefore, this study was conducted to evaluate the prevalence of HEV among adults in South-West of Iran.Methods. Blood samples
were taken from510 participants, 206 (40.4%)males and 304 (59.6%) females fromFebruary to July 2014.Detection of anti-HEV IgG
and IgM antibodies was carried out by ELISA test.Results.The overall anti-HEV IgG and IgMprevalence rates were 46.1% and 1.4%,
respectively. Anti-HEV IgGand IgM seropositivitywere not statistically associatedwith gender and race/ethnicity.Meanwhile, there
were significant differences between the age groups regarding HEV IgG and IgM seropositivity. HEV IgG seroprevalence increased
with age from 14.3% in subjects aged 18–30 years to 71.4% in persons over 71 years old, and considerably individuals aged 61 to 70
years had the highest HEV prevalence (90.9%). Also, 5.7% in the age group 18–30 years and 2.2% in the age group 31–40 years were
positive for anti-HEV IgM antibodies and the highest rate was observed in subjects aged 18–30 years. Conclusion. In conclusion,
high HEV IgG seroprevalence of 46.1% was observed among adults in South-West of Iran.
1. Introduction
Hepatitis E virus (HEV) is a nonenveloped, single stranded
RNA virus which belongs to the Hepeviridae family [1].
HEV is a causative agent for acute hepatitis in one-third of
the world’s population and fulminant hepatitis in pregnant
women [2].The virion is relatively resistant to environmental
conditions and remains infectious even in rough situation
such as sewage [3]. Therefore the major route of HEV
transmission is the ingestion of the fecal contaminated
water; however, HEV can be spread zoonotically and by
blood transfusion especially in industrialized countries [4].
Although there is an inclusive debate on the parental route of
transmission, available evidence seems to prove the ability of
the virus to cause congenital infections [5].
HEV infection is a significant public health concern
especially in developing countries, where large outbreaks as
a result of poor sanitation and lack of sewage infrastructures
have been reported [6].There is also a growing support for the
claims that seroprevalence of HEV infection in industrialized
countries is increasing [6].
The clinical symptoms of HEV infection resemble other
hepatotropic viruses which cause hepatitis [7]. Patients with
chronic liver disease, travelers to endemic areas, and people
working with animals like pigs, cows, sheep, and goats are
at high risk of HEV infection [5, 8–10]. Pregnant women
infected in third semester develop fulminant hepatic failure
particularly in the endemic areas of HEV infection [11, 12].
Iran is an endemic country for hepatitis E infection [7, 13],
but HEV prevalence has not been determined among general
population in all parts of this country. Most conducted
studies in Iran have reported the HEV prevalence in specific
groups and studies onHEVprevalence in general populations
are limited. HEV prevalence information in general popula-
tion can be a better indicator of the public health and hygiene.
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Number of anti-HEV IgG
positive subjects (%): 235
(46.1%)
Number of anti-HEV IgG




Male 206 (40.4%) 86 (41.7%) 120 (58.3%)
Female 304 (59.6%) 149 (49%) 155 (51%)
Race 0.168
Arab 274 (53.7%) 134 (48.9%) 140 (51.1%)
Farsi 236 (46.3%) 101 (42.8%) 135 (57.2%)
Age groups (years) <0.001
18–30 70 (13.7%) 10 (14.3%) 60 (85.7%)
31–40 135 (26.5%) 25 (18.5%) 110 (81.5%)
41–50 135 (26.5%) 55 (40.7%) 80 (59.3)
51–60 80 (15.7%) 70 (87.5%) 10 (12.5%)
60–71 55 (10.8%) 50 (90.9%) 5 (9.1%)
>71 35 (6.9%) 25 (71.4%) 10 (28.6%)
Ahvaz is a large city in the South-West of Iran with a
population of about 1.18 million inhabitants that consists of
two ethnic groups: Arab and Farsi. Ahvaz is located in the
banks of the Karun River, which is the main river in this area.
No data is available so far on the prevalence of HEV among
general population of Ahvaz city; therefore this study was
conducted to determine the prevalence of HEV among adults
in South-West of Iran.
2. Material and Methods
This cross-sectional study was approved by the Ethical
Committee of Ahvaz Jundishapur University of Medical
Science with research Project number 91112. To estimate
the prevalence of anti-HEV IgG and IgM antibodies in the
general population of Ahvaz city, 510 blood samples from
the adult population of Ahvaz city were collected randomly
using the multistage cluster sampling method from February
to July 2014. Ahvaz is a large city in the South-West of Iran
that consists of 8 districts and has 94 public health centers. In
the first stage, 4 public health centers were selected randomly
from each district. In the next stage, the family registry
code was used to randomly select 16 households within
each public health center. From each family, one subject
was selected randomly. The trained interviewers visited the
subjects in their homes and completed a questionnaire
containing information of age, gender, and race/ethnicity
for each individual. In addition, the informed consent was
obtained from all participants. The subjects who refused to
participate in the study were replaced with the next random
participants. Blood samples were taken from participants.
The serum samples were tested in duplicate for anti-HEV IgG
and IgM antibodies by using DIA.PRO HEV Ab ELISA kit
and HEV IgM ELISA kit (DIA.PRO, Italy) according to the
manufacturer’s instructions.
Statistical analyses were performed using SPSS 17 Package
program (SPSS Inc., Chicago, IL, USA) and 𝑃 values of less
than 0.05 were considered statistically significant. Data were
analyzed and compared by descriptive statistics and Chi-
square test or Fisher’s exact test. All data were presented as
frequencies or percentage.
3. Results
Out of 510 study subjects, 206 (40.4%) were male and 304
(59.6%) were female. The average age of participants was
varying from 18 to 81 years while the mean age ± SD was
45.89 ± 14.63 years. The subjects were classified into six age
groups: 18–30, 31–40, 41–50, 51–60, 61–70, and over 71 years.
70 (13.7%) subjects were between 18 and 30 years old, while
135 (26.5%) were between 31 and 40 years old, 135 (26.5%)
were between 41 and 50 years old, 80 (15.7%) were between
51 and 60 years old, 55 (10.8%) were between 61 and 70
years old, and 35 (6.9%) were older than 71 years. Based on
race/ethnicity, 53.7% (274) of cases were Arab and 46.3%
(236)were Farsi. General characteristics of all participants are
summarized in Table 1. Of the 510 subjects, 235 (46.1%) are
shown to be positive for anti-HEV IgG antibody by DIA.PRO
HEV Ab ELISA kit, while 275 (53.9%) were negative. The
overall anti-HEV IgG prevalence rate was 46.1%.
With regard to gender and race, 86/206 (41.7%) in the
male group and 149/304 (49%) in the female group were
positive for anti-HEV IgG antibodies. 134/274 (48.9%) in the
Arab group and 101/236 (42.8%) in the Farsi group are shown
to be positive for anti-HEV IgG antibody. However, the
seroprevalence was higher among Arab and female groups;
HEV seropositivity was not statistically associated with gen-
der (𝑃 = 0.106) and race (𝑃 = 0.168). Meanwhile, there
was statistical difference in anti-HEV IgG seroprevalence rate
between the subjects grouped according to age (𝑃 < 0.001),
so that seroprevalence of HEV increased with age from 14.3%
(10/70) in subjects aged 18–30 years to 71.4% (25/35) in
persons over 71 years old, with a peak among 61–70 year-olds
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Number of anti-HEV IgM
positive subjects (%): 7
(1.4%)
Number of anti-HEV IgM




Male 206 (40.4%) 4 (1.9%) 202 (98.1%)
Female 304 (59.6%) 3 (1%) 301 (99%)
Race 0.130
Arab 274 (53.7%) 6 (2.2%) 268 (97.8%)
Farsi 236 (46.3%) 1 (0.4%) 235 (99.6%)
Age groups (years) 0.012
18–30 70 (13.7%) 4 (5.7%) 66 (94.3%)
31–40 135 (26.5%) 3 (2.2%) 132 (97.8%)
41–50 135 (26.5%) 0 135 (100%)
51–60 80 (15.7%) 0 80 (100%)
60–71 55 (10.8%) 0 55 (100%)
>71 35 (6.9%) 0 35 (100%)
(90.9%, 50/55). The highest rate of anti-HEV seroprevalence
was seen in subjects aged 61–70 years (Table 1).
When we evaluated anti-HEV IgM antibody seropreva-
lence rate in the gender and race groups, no significant
differences were observed between the subjects regarding
gender (1% in females and 1.9% in males, 𝑃 = 0.448) and race
(2.2% in Arab and 0.4% in Farsi, 𝑃 = 0.130).
However, with regard to age, 4/70 (5.7%) in the age group
18–30 years and 3/135 (2.2%) in the age group 31–40 years
were positive for anti-HEV IgM antibodies. There was a
significant difference between the age groups regarding HEV
seropositivity (𝑃 = 0.012). The highest rate of anti-HEV
seroprevalence was observed in subjects aged 18–30 years
(Table 2). Overall, 7 blood samples (1.4%) are shown to be
positive for HEV-specific-IgM antibodies, while 503 samples
(98.6%) were negative.
4. Discussion
Hepatitis E infection is a worldwide public health concern,
which causes large outbreaks of acute hepatitis in developing
countries especially Asia, Middle East, and Africa and also
sporadic cases of the infection in developed countries such
as South America and Europe [9]. Although HEV is mainly
transmitted via the fecal-oral route especially contaminated
water in endemic areas, transmission via the blood transfu-
sion has also been suggested according to the high prevalence
of anti-HEV IgG among blood donors [4, 13, 14].
Epidemiological studies in different parts of the world
show the wide variation in HEV prevalence patterns, though
the HEV seroprevalence rates are higher among less devel-
oped countries [15]. High prevalence rates are often reported
from South Asia, Egypt in the Middle East, and the Far East
except Japan, and low rates are often found in Europe and
the Americas [16]. Iran is an endemic country for hepatitis
E infection [7, 13], since HEV seroprevalence in general
population is above 5% [7]. Previous studies have reported
various HEV prevalence rates in different regions of Iran.
Ataei et al. in 2005 reported HEV seroprevalence rate of
3.8% among general population in IsfahanProvince, Iran [17].
Assarehzadegan et al. in 2005 reported HEV prevalence rate
of 11.5% among blood donors in Khuzestan Province [15]. In
Mohebbi et al. study, HEV prevalence was 9.3% in general
population of Tehran [18]. In another study byNazer et al., the
prevalence of HEV was reported to be 7.8% in Khorramabad
city in 2009 [19].
Regarding HEV prevalence among the general popu-
lation of other countries, the overall HEV prevalence rate
was reported to be 22.5% among general population in
Bangladesh by Labrique et al. [20], about 3.20% in French
blood donors by Boutrouille et al. [21], 13% in the general
population in England by Ijaz et al. [22], 1.9% in the general
population in Netherlands [23], and 5.3% in the general
population of Japan [24].
In the present study we investigated the HEV seropreva-
lence among adult population in Ahvaz city and found that
anti-HEV IgG and IgM seroprevalence were 46.1% and 1.4%,
respectively. The result of the current study is considerably
higher than that reported among adults in other parts of
Iran [16]: 9.3% in Nahavand [25], 8.1% in Isfahan [17], 7.8%
in Western Iran [26], 7.3% in sari [27], and 7.9–15% in
Tehran [28]; it is also higher than that reported among adult
population of some other countries: 3.9% inUnited Kingdom
[16], 16.8% in Germany [29], 7.3% in Spain [30], about 20% in
Korea [31], 23% in Thailand [32], 39–42% in USA [33], and
5.9% in Turkey [16]; however, it is lower than that reported
among rural population older than four years in Egypt (51–
78%) [16, 34], pregnant women in Nile Delta, Egypt (84%)
[16, 35], general population older than 11 years in central
Malaysia (50–67%) [16], tribes population (50–100%) and
adult population (16–77%) in Andaman Islands, India [16],
and homeless children in Cochabamba city, Bolivia (66%)
[16].
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However, a part of this difference may be due to differ-
ences in the used ELISA detection kits, the time of sampling,
and the demographics and size of studied population. Over-
all, our results compared with the previous studies from Iran
indicate that the geographic distribution of HEV infection
is different even within a specific country, which most likely
reflects different levels of exposure to infection over time due
to different living conditions in different regions and fecal-
oral transmission of HEV. In the current study, the HEV
seroprevalence rate significantly increased with age from
14.3% in people aged below 31 years to 90.9% in persons
aged 61–70 years. Improvement of public health and hygiene
results in decreased exposure to the virus over time.However,
exposure to HEV increases with age. This is consistent with
most studieswhich reported a significant association between
age and higher anti-HEVpositive values, since the prevalence
of the disease increases with age [26, 29, 31, 36]. Similarly
high seroprevalence was found among adult population older
than 60 years in China (70–80%), adult population older than
80 years in Bangladesh (67%), and adult population older
than 80 years in Hong Kong (52–60%) [16]. Similar to the
results of previous studies [5, 13, 17, 29, 37], our results show
that the presence of anti-HEV IgG and IgM antibodies is not
associated with gender; also we did not find any association
between race/ethnicity and HEV seropositivity.
Our data showed that the anti-HEV IgG prevalence rate
among adult population in Ahvaz is 46.1%, the highest rate
reported in different parts of Iran. The implication is that
Ahvaz city is a highly endemic area for HEV and the main
route of HEV transmission in this city is most likely Karun
River. Evidence for this claim is that the drinkingwater source
of the city is supplied from Karun River and this river is
commonly used for swimming, fishing, and other household
needs by inhabitants. Moreover, the city sewage is discharged
in the river. Since the major transmission route of HEV is
most often the fecal contaminated drinking water and also
this virus is relatively resistant to environmental conditions
and remains infectious in sewage, the river can be considered
as the water source for HEV infection. However more studies
are required to confirm this hypothesis. Therefore, type E
hepatitis is more common among adult population of Ahvaz
city compared with other parts of Iran and this finding
should be considered in the differential diagnosis of hepatitis
infections and also prediction of possible outbreaks.
5. Conclusion
In conclusion, high anti-HEV IgG seroprevalence of 46.1%
was observed among the adults population living in Ahvaz
city of Iran. Determination of HEV prevalence in different
regions can be used for the purpose of HEV epidemiology by
developing a prevalence map on the base of HEV geograph-
ical distribution. In addition to epidemiological purposes,
HEV prevalence information is important in evaluating the
public health and hygiene and in identifying the major route
of HEV transmission in Iran. However, further studies are
required to evaluate these topics.
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